Literature DB >> 9010032

'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease.

P J Johnson1, N Leung, P Cheng, C Welby, W T Leung, W Y Lau, S Yu, S Ho.   

Abstract

The only hope for effective treatment of hepatocellular carcinoma (HCC or 'hepatoma') lies in early diagnosis. Measurement of the serum alphafetoprotein (AFP) level is potentially a useful screening test. When grossly raised, it is almost diagnostic of HCC. However, modestly elevated levels may also arise in patients with benign chronic liver disease, and this markedly decreases the test's specificity and hence its clinical value. In 582 consecutive attendees at an outpatient clinic for people with chronic liver disease, a single blood sample was taken for analysis of 'total' AFP and the 'hepatoma-specific' AFP isoform. Using ultrasonography as the primary screening method, patients with AFP levels > or = 50 ng ml-1 were followed up throughout the study or until HCC was diagnosed on the basis of conventionally defined criteria. On entry into the study, 53 patients had an AFP concentration > = or 50 ng ml-1 and the 'hepatoma-specific' AFP isoform was detected in 26 of these. During an 18-month follow-up period, a diagnosis of HCC was established by conventional methods in 19 (17 'definite' and two 'probable') of these 26 patients. In only two cases was there ultrasound evidence of tumour development at the time AFP was first found to be elevated; in the remainder a diagnosis of HCC, based on ultrasound screening, was established at a median time of 3.6 months (range 1-18 months) after entry into the study. Among those 27 without the 'hepatoma-specific' isoform, one developed a 'definite' HCC and two developed 'probable' tumours. With the application of 'hepatoma-specific' AFP, the positive predictive value of the test was 73.1%, compared with only 41.5% using the conventional 'total' AFP test. Application of this test for the 'hepatoma-specific' AFP markedly increases the positive predictive value of AFP and, in some cases, permits the presence of tumour to be inferred before it could be detected by routine ultrasound examination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010032      PMCID: PMC2063272          DOI: 10.1038/bjc.1997.39

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma.

Authors:  H S Lee; Y H Chung; C Y Kim
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

2.  Concanavalin A affinity of alpha-fetoprotein. Its use in differentiating tumors.

Authors:  S Govindarajan; T L Fong; M Ashcavai
Journal:  Am J Clin Pathol       Date:  1987-12       Impact factor: 2.493

3.  alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma.

Authors:  A S Lok; C L Lai
Journal:  Hepatology       Date:  1989-01       Impact factor: 17.425

4.  Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis.

Authors:  H Oka; N Kurioka; K Kim; T Kanno; T Kuroki; Y Mizoguchi; K Kobayashi
Journal:  Hepatology       Date:  1990-10       Impact factor: 17.425

5.  Differential alpha-fetoprotein lectin binding in hepatocellular carcinoma. Diagnostic utility at low serum levels.

Authors:  M Q Du; W L Hutchinson; P J Johnson; R Williams
Journal:  Cancer       Date:  1991-01-15       Impact factor: 6.860

6.  Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma.

Authors:  Y Aoyagi; M Isemura; Z Yosizawa; Y Suzuki; C Sekine; T Ono; F Ichida
Journal:  Biochim Biophys Acta       Date:  1985-08-23

7.  Carbohydrate structure of the concanavalin A molecular variants of alpha-fetoprotein.

Authors:  T Krusius; E Ruoslahti
Journal:  J Biol Chem       Date:  1982-04-10       Impact factor: 5.157

8.  Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study.

Authors:  Y F Liaw; D I Tai; C M Chu; D Y Lin; I S Sheen; T J Chen; C C Pao
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

9.  Lentil-lectin-reactive alpha-fetoprotein in the differential diagnosis of benign and malignant liver disease.

Authors:  P K Buamah; R Harris; O F James; A W Skillen
Journal:  Clin Chem       Date:  1986-11       Impact factor: 8.327

10.  Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins.

Authors:  K Taketa; M Izumi; E Ichikawa
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

View more
  17 in total

1.  Future perspectives for hepatocellular carcinoma.

Authors:  W Y Lau
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

2.  Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma.

Authors:  Kok Sun Looi; Ernesto S Nakayasu; Raquel A de Diaz; Eng M Tan; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2008-08-02       Impact factor: 4.466

3.  A cancer-related protein 14-3-3ζ is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma.

Authors:  Mei Liu; Xinxin Liu; Pengfei Ren; Jitian Li; Yurong Chai; Su-Jun Zheng; Yu Chen; Zhong-Ping Duan; Ning Li; Jian-Ying Zhang
Journal:  Tumour Biol       Date:  2014-01-04

4.  Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma.

Authors:  Jian-Ying Zhang; Roxanne Megliorino; Xuan-Xian Peng; Eng M Tan; Yao Chen; Edward K L Chan
Journal:  J Hepatol       Date:  2006-09-25       Impact factor: 25.083

5.  Recent developments in the first detection of hepatocellular carcinoma.

Authors:  Joseph B Lopez
Journal:  Clin Biochem Rev       Date:  2005-08

6.  Using immunoproteomics to identify alpha-enolase as an autoantigen in liver fibrosis.

Authors:  Bo Peng; Xueyong Huang; Ernesto S Nakayasu; John R Petersen; Suimin Qiu; Igor C Almeida; Jian-Ying Zhang
Journal:  J Proteome Res       Date:  2013-03-15       Impact factor: 4.466

7.  Diagnosis of hepatocellular carcinoma.

Authors:  Eldad S Bialecki; Adrian M Di Bisceglie
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

8.  Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma.

Authors:  K Wang; Y Chen; S Liu; S Qiu; S Gao; X Huang; J Zhang; X Peng; W Qiani; J Y Zhang
Journal:  Int J Immunopathol Pharmacol       Date:  2009 Jul-Sep       Impact factor: 3.219

9.  Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma.

Authors:  Yao Chen; Yusen Zhou; Suimin Qiu; Kaijuan Wang; Siwei Liu; Xuan-Xian Peng; Junfeng Li; Eng M Tan; Jian-Ying Zhang
Journal:  Cancer Lett       Date:  2009-08-15       Impact factor: 8.679

10.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.